Perioperative management of antithrombotic and antiplatelet therapy.
作者信息
Bracey Arthur W
出版信息
Tex Heart Inst J. 2015 Jun 1;42(3):239-42. doi: 10.14503/THIJ-15-5066. eCollection 2015 Jun.
Abstract
摘要
相似文献
1
Perioperative management of antithrombotic and antiplatelet therapy.
Tex Heart Inst J. 2015 Jun 1;42(3):239-42. doi: 10.14503/THIJ-15-5066. eCollection 2015 Jun.
2
Novel antiplatelet and anticoagulant agents in the cardiac care unit.
Cardiol Clin. 2013 Nov;31(4):533-44, viii. doi: 10.1016/j.ccl.2013.07.001. Epub 2013 Aug 9.
3
[Bridging: Perioperative management of chronic anticoagulation or antiplatelet therapy].
Dtsch Med Wochenschr. 2014 Jun;139(24):1301-6. doi: 10.1055/s-0034-1370110. Epub 2014 Jun 3.
4
A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons.
J Am Acad Dermatol. 2015 Mar;72(3):524-34. doi: 10.1016/j.jaad.2014.10.027. Epub 2014 Dec 6.
5
Perioperative management of warfarin and antiplatelet therapy.
Cleve Clin J Med. 2009 Nov;76 Suppl 4:S37-44. doi: 10.3949/ccjm.76.s4.07.
6
A review of oral anticoagulants in patients with atrial fibrillation.
Postgrad Med. 2012 Nov;124(6):7-16. doi: 10.3810/pgm.2012.11.2608.
7
New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
Neurol Clin. 2013 Aug;31(3):659-75. doi: 10.1016/j.ncl.2013.03.001.
8
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.
9
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7.
10
Safety of new oral anticoagulants with dual antiplatelet therapy in patients with acute coronary syndromes.
Ann Pharmacother. 2013 Apr;47(4):573-7. doi: 10.1345/aph.1R576. Epub 2013 Apr 2.
引用本文的文献
1
Influence of acetylsalicylic acid and low-molecular weight heparins on the formation of renal hematoma after shock wave lithotripsy.
World J Urol. 2017 Dec;35(12):1939-1946. doi: 10.1007/s00345-017-2070-0. Epub 2017 Jul 12.
本文引用的文献
1
Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study.
Fundam Clin Pharmacol. 2015 Feb;29(1):106-11. doi: 10.1111/fcp.12088. Epub 2014 Sep 25.
2
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question.
Blood. 2013 Dec 5;122(24):3879-83. doi: 10.1182/blood-2013-07-518423. Epub 2013 Dec 4.
3
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
J Am Coll Cardiol. 2014 Feb 4;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104. Epub 2013 Sep 27.
4
Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
Circulation. 2013 Sep 10;128(11):1234-43. doi: 10.1161/CIRCULATIONAHA.113.002283. Epub 2013 Aug 9.
5
How I treat anticoagulated patients undergoing an elective procedure or surgery.
Blood. 2012 Oct 11;120(15):2954-62. doi: 10.1182/blood-2012-06-415943. Epub 2012 Aug 28.
6
Clinical experience with oral versus intravenous vitamin K for warfarin reversal.
Transfusion. 2013 Mar;53(3):491-8; quiz 490. doi: 10.1111/j.1537-2995.2012.03755.x. Epub 2012 Jun 28.
7
Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.
Am J Clin Pathol. 2012 Apr;137(4):572-4. doi: 10.1309/AJCPAU7OQM0SRPZQ.
8
Apixaban versus warfarin in patients with atrial fibrillation.
N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
9
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
10
International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy.
Arch Pathol Lab Med. 2011 Apr;135(4):490-4. doi: 10.5858/2009-0474-OA.1.
Zotero 插件